Therapeutic Fusion Proteins.
biologics
fusion proteins
therapeutic proteins
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
30 11 2023
30 11 2023
Historique:
received:
17
08
2023
accepted:
08
11
2023
medline:
4
12
2023
pubmed:
1
12
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
Therapeutic fusion proteins are a class of hybrid constructs that combine distinct biomolecules into a single platform with the additive effects of the components. The ability to fuse two unrelated proteins provides a means to localize mechanisms to better treat a range of diseases. Fusion proteins can be designed to impart diverse functions, including increasing half-life, providing targeting, and enabling sustained signaling. Of these, half-life extenders, which are fused to a therapeutic protein to increase exposure, are the most established group of fusion proteins, with many clinical successes. Rapid advances in antibody and antibody-derivative technology have enabled the fusion of targeting domains with therapeutic proteins. An emerging group of therapeutic fusion proteins has two separate active functions. Although most research for therapeutic fusion proteins focuses on cancer, prior successes provide a foundation for studies into other diseases as well. The exponential emergence of biopharmaceuticals gives precedence for increased research into therapeutic fusion proteins for a multitude of diseases.
Identifiants
pubmed: 38036919
doi: 10.1208/s12248-023-00873-8
pii: 10.1208/s12248-023-00873-8
doi:
Substances chimiques
Proteins
0
Antibodies
0
Recombinant Fusion Proteins
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM134069
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA256460
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Strohl WR. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs. 2015;29(4):215–39.
pubmed: 26177629
pmcid: 4562006
doi: 10.1007/s40259-015-0133-6
Vaishya R, Khurana V, Patel S, Mitra AK. Long-term delivery of protein therapeutics. Expert Opin Drug Deliv. 2015;12(3):415–40.
pubmed: 25251334
doi: 10.1517/17425247.2015.961420
Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868–76.
pubmed: 21862310
doi: 10.1016/j.copbio.2011.06.012
Duivelshof BL, Murisier A, Camperi J, Fekete S, Beck A, Guillarme D, D’Atri V. Therapeutic Fc-fusion proteins: current analytical strategies. J Sep Sci. 2021;44(1):35–62.
pubmed: 32914936
doi: 10.1002/jssc.202000765
Wilkinson I, Hale G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. mAbs. 2022;14(1):2123299.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25.
pubmed: 17703228
doi: 10.1038/nri2155
Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis. 2000;59(90001):46i–49.
doi: 10.1136/ard.59.suppl_1.i46
Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003;49(2, Supplement):105–11.
doi: 10.1016/mjd.2003.554
Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45(5):490–7.
pubmed: 15831771
doi: 10.1177/0091270004273321
Jafari R, Zolbanin NM, Rafatpanah H, Majidi J, Kazemi T. Fc-fusion proteins in therapy: an updated view. Curr Med Chem. 2017;24(12):1228–37.
pubmed: 28088904
doi: 10.2174/0929867324666170113112759
Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15–32.
pubmed: 28421387
doi: 10.1007/s13238-017-0408-4
Siriwattananon K, Manopwisedjaroen S, Kanjanasirirat P, Budi Purwono P, Rattanapisit K, Shanmugaraj B, Smith DR, Borwornpinyo S, Thitithanyanont A, Phoolcharoen W. Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2. Front Plant Sci. 2021;11:604663.
pubmed: 33584747
pmcid: 7874119
doi: 10.3389/fpls.2020.604663
Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupančić-Šalek S, Oldenburg J, Chowdary P. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022;6(11):3422–32.
pubmed: 35290453
pmcid: 9198939
doi: 10.1182/bloodadvances.2021006403
Malec L, Van Damme A, Chan AKC, Spasova M, Jain N, Sensinger C, Dumont J, Lethagen S, Carcao M, Peyvandi F. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood. 2023;141(16):1982–9.
pubmed: 36735911
pmcid: 10646781
doi: 10.1182/blood.2022017780
Guo M, Wang R, Geng J, Li Z, Liu M, Lu X, Wei J, Liu M. Human TFF2-Fc fusion protein alleviates DSS-induced ulcerative colitis in C57BL/6 mice by promoting intestinal epithelial cells repair and inhibiting macrophage inflammation. Inflammopharmacology. 2023;31(3):1387–404.
pubmed: 37129719
pmcid: 10153040
doi: 10.1007/s10787-023-01226-9
Heise T, Chien J, Beals JM, Benson C, Klein O, Moyers JS, Haupt A, Pratt EJ. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023;25(4):1080–90.
pubmed: 36541037
doi: 10.1111/dom.14956
Jin J, Cui G, Mi N, Wu W, Zhang X, Xiao C, Wang J, Qiu X, Han M, Li Z, Wang L, Lu T, Niu H, Wu Z, Li J. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects. Eur J Pharm Sci. 2023;185:106448.
pubmed: 37062422
doi: 10.1016/j.ejps.2023.106448
Nilvebrant J, Hober S. The albumin-binding domain as a scaffold for protein engineering. Comput Struct Biotechnol J. 2013;6:e201303009.
pubmed: 24688717
pmcid: 3962080
doi: 10.5936/csbj.201303009
Fala L. Tanzeum (Albiglutide): a once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015;8(Spec Feature):126–30.
pubmed: 26629277
pmcid: 4665069
Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88(1):220–4.
pubmed: 12519856
doi: 10.1210/jc.2002-021053
Tan H, Su W, Zhang W, Zhang J, Sattler M, Zou P. Albumin-binding domain extends half-life of glucagon-like peptide-1. Eur J Pharmacol. 2021;890:173650.
pubmed: 33049303
doi: 10.1016/j.ejphar.2020.173650
Xia J, Gao G, Zhang C, Ying J, Li J. Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo. Eur J Pharm Sci. 2023;185:106422.
pubmed: 36906110
doi: 10.1016/j.ejps.2023.106422
Xu D, Wu H, Zhou C. Fusion of parathyroid hormone (1–34) to an albumin-binding domain improves osteogenesis. J Drug Deliv Sci Technol. 2023;79:104019.
doi: 10.1016/j.jddst.2022.104019
Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci Transl Med. 2020;12(565):eabb0580.
pubmed: 33055243
doi: 10.1126/scitranslmed.abb0580
Tao H-Y, Wang R-Q, Sheng W-J, Zhen Y-S. The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy. Int J Biol Macromol. 2021;187:24–34.
pubmed: 34284054
doi: 10.1016/j.ijbiomac.2021.07.080
Sockolosky JT, Kivimäe S, Szoka FC. Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. PLoS ONE. 2014;9(7):e102566.
pubmed: 25057984
pmcid: 4109916
doi: 10.1371/journal.pone.0102566
Amidzadeh Z, Rismani E, Shokrgozar MA, Rahimi H, Golkar M. In silico design of fusion keratinocyte growth factor containing collagen-binding domain for tissue engineering application. J Mol Graph Model. 2023;118:108351.
pubmed: 36308945
doi: 10.1016/j.jmgm.2022.108351
Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Ann Rev Pharmacol Toxicol. 2015;55(1):489–511.
doi: 10.1146/annurev-pharmtox-010611-134654
Arlotta KJ, Owen SC. Antibody and antibody derivatives as cancer therapeutics. WIREs Nanomedicine Nanobiotechnol. 2019;11(5):e1556.
doi: 10.1002/wnan.1556
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Disc. 2019;18(8):585–608.
doi: 10.1038/s41573-019-0028-1
Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616.
pubmed: 34025638
pmcid: 8131538
doi: 10.3389/fimmu.2021.626616
Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37.
pubmed: 17426506
pmcid: 2785020
doi: 10.1097/AIA.0b013e318034194e
Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf. 1995;13(6):371–406.
pubmed: 8652081
doi: 10.2165/00002018-199513060-00006
Martomo SA, Lu D, Polonskaya Z, Luna X, Zhang Z, Feldstein S, Lumban-Tobing R, Almstead DK, Miyara F, Patel J. Single-dose anti-PD-L1/IL-15 fusion protein KD033 generates synergistic antitumor immunity with robust tumor-immune gene signatures and memory responses. Mol Cancer Ther. 2021;20(2):347–56.
pubmed: 33293344
doi: 10.1158/1535-7163.MCT-20-0457
Zhou Y, Quan G, Liu Y, Wang Z, Shi N, Wu Y, Liu Q, Gao X, Zhang R, Luo L. Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety. Int Immunopharmacol. 2023;115:109634.
pubmed: 36584573
doi: 10.1016/j.intimp.2022.109634
Venetz D, Koovely D, Weder B, Neri D. Targeted reconstitution of cytokine activity upon antigen binding using split cytokine antibody fusion proteins. J Biol Chem. 2016;291(35):18139–47.
pubmed: 27402834
pmcid: 5000063
doi: 10.1074/jbc.M116.737734
Quijano-Rubio A, Bhuiyan AM, Yang H, Leung I, Bello E, Ali LR, Zhangxu K, Perkins J, Chun J-H, Wang W, Lajoie MJ, Ravichandran R, Kuo Y-H, Dougan SK, Riddell SR, Spangler JB, Dougan M, Silva D-A, Baker D. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nat Biotechnol. 2023;41(4):532–40.
pubmed: 36316485
doi: 10.1038/s41587-022-01510-z
Murer P, Neri D. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. New Biotechnol. 2019;52:42–53.
doi: 10.1016/j.nbt.2019.04.002
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16(2):139–49.
pubmed: 15863030
doi: 10.1016/j.cytogfr.2005.01.001
Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625(1):41–54.
pubmed: 19837059
pmcid: 2783916
doi: 10.1016/j.ejphar.2009.09.067
Liu J, Meng Z, Xu T, Kuerban K, Wang S, Zhang X, Fan J, Ju D, Tian W, Huang X, Huang X, Pan D, Chen H, Zhao W, Ye L. A SIRPαFc fusion protein conjugated with the collagen-binding domain for targeted immunotherapy of non-small cell lung cancer. Front Immunol. 2022;13:845217.
pubmed: 35422796
pmcid: 9002095
doi: 10.3389/fimmu.2022.845217
Jacob A, Shen L, He J, Nealon K, Alexander JJ, Ambrus JL. Effect of lymphotoxin blockage on different stages of Sjogren’s syndrome in an animal model. Rheumatol Autoimmun. 2022;02(02):76–81.
doi: 10.1002/rai2.12041
Han L, Zhang X-Z, Wang C, Tang X-Y, Zhu Y, Cai X-Y, Wu Y-J, Shu J-L, Wang Q-T, Chen J-Y, Chang Y, Wu H-X, Zhang L-L, Wei W. IgD-Fc-Ig fusion protein, a new biological agent, inhibits T cell function in CIA rats by inhibiting IgD-IgDR-Lck-NF-κB signaling pathways. Acta Pharmacol Sin. 2020;41(6):800–12.
pubmed: 31937932
pmcid: 7470893
doi: 10.1038/s41401-019-0337-2
Hu X-X, Zhang A-J, Pan W-W, Xin Q-L, Chen J-Y, Zhang L-L, Chang Y, Wu Y-J, Wei W. An IgD-Fc-Ig fusion protein restrains the activation of T and B cells by inhibiting IgD-IgDR-Lck signaling in rheumatoid arthritis. Acta Pharmacol Sin. 2022;43(2):387–400.
pubmed: 33864023
doi: 10.1038/s41401-021-00665-w
Qu T, Li B, Wang Y. Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed. Biomark Res. 2022;10(1):20.
pubmed: 35418166
pmcid: 9009010
doi: 10.1186/s40364-022-00373-5
Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, Gupta A, Vardeu A, Leach E, Naidoo R, Stanhope S, Lewis S, Hurst J, O’Kelly I, Sznol M. Tebentafusp, A TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869–78.
pubmed: 32816891
pmcid: 9210997
doi: 10.1158/1078-0432.CCR-20-1247
Lv Z, Zhang P, Li D, Qin M, Nie L, Wang X, Ai L, Feng Z, Odhiambo WO, Ma Y, Ji Y. CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. OncoImmunology. 2020;9(1):1747688.
pubmed: 32363119
pmcid: 7185221
doi: 10.1080/2162402X.2020.1747688
Zhang R, Pei P, Wang Y, Guo Q, Luo SZ, Chen L. A single-chain variable fragment-anticancer lytic peptide (scFv-ACLP) fusion protein for targeted cancer treatment. Chem Biol Drug Des. 2023;101(6):1406–15.
pubmed: 36862057
doi: 10.1111/cbdd.14223
Bruno S, Margiotta M, Cozzolino M, Bianchini P, Diaspro A, Cavanna L, Tognolini M, Abbruzzetti S, Viappiani C. A photosensitizing fusion protein with targeting capabilities. Biomol Concepts. 2022;13(1):175–82.
pubmed: 35355498
doi: 10.1515/bmc-2022-0014
Mehrab R, Sedighian H, Sotoodehnejadnematalahi F, Halabian R, Fooladi AAI. A comparative study of the arazyme-based fusion proteins with various ligands for more effective targeting cancer therapy: an in-silico analysis. Res Pharm Sci. 2023;18(2):159–76.
pubmed: 36873271
pmcid: 9976060
doi: 10.4103/1735-5362.367795
Ahmadzadeh M, Mohit E. Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer. Biotechnol Lett. 2023;45(3):371–85.
pubmed: 36650341
doi: 10.1007/s10529-022-03342-y
Baig MH, Adil M, Khan R, Dhadi S, Ahmad K, Rabbani G, Bashir T, Imran MA, Husain FM, Lee EJ, Kamal MA, Choi I. Enzyme targeting strategies for prevention and treatment of cancer: implications for cancer therapy. Semin Cancer Biol. 2019;56:1–11.
pubmed: 29248538
doi: 10.1016/j.semcancer.2017.12.003
Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Prim. 2018;4(1):27.
pubmed: 30275469
doi: 10.1038/s41572-018-0025-4
Zhou Z, Austin GL, Shaffer R, Armstrong DD, Gentry MS. Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases. Trends Mol Med. 2019;25(12):1094–109.
pubmed: 31522955
pmcid: 6889062
doi: 10.1016/j.molmed.2019.08.005
Bagshawe KD. Antibody-directed enzyme prodrug therapy: a review. Drug Dev Res. 1995;34(2):220–30.
doi: 10.1002/ddr.430340211
Alqahtani AD, Al-Mansoori L, Bashraheel SS, Rashidi FB, Al-Yafei A, Elsinga P, Domling A, Goda SK. Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment. Eur J Pharm Sci. 2019;127:79–91.
pubmed: 30343151
doi: 10.1016/j.ejps.2018.10.014
Nervig CS, Hatch ST, Owen SC. Complementation dependent enzyme prodrug therapy enables targeted activation of prodrug on HER2-positive cancer cells. ACS Med Chem Lett. 2022;3(11):1769–75.
doi: 10.1021/acsmedchemlett.2c00394
Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11(1):5820.
pubmed: 33199717
pmcid: 7670458
doi: 10.1038/s41467-020-19505-2
Rihtar E, Lebar T, Lainšček D, Kores K, Lešnik S, Bren U, Jerala R. Chemically inducible split protein regulators for mammalian cells. Nat Chem Biol. 2023;19(1):64–71.
pubmed: 36163385
doi: 10.1038/s41589-022-01136-x
Brezgin S, Kostyusheva A, Kostyushev D, Chulanov V. Dead Cas systems: types, principles, and applications. Int J Mol Sci. 2019;20(23):6041.
pubmed: 31801211
pmcid: 6929090
doi: 10.3390/ijms20236041
Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237–51.
pubmed: 23498934
pmcid: 3640494
doi: 10.1016/j.cell.2013.02.014
Jiang H-K, Ambrose NL, Chung CZ, Wang Y-S, Söll D, Tharp JM. Split aminoacyl-tRNA synthetases for proximity-induced stop codon suppression. Proc Natl Acad Sci. 2023;120(8):e2219758120.
pubmed: 36787361
pmcid: 9974479
doi: 10.1073/pnas.2219758120
Nousiainen A, Schenkwein D, Ylä-Herttuala S. Characterization of a new IN-I-PpoI fusion protein and a homology-arm containing transgene cassette that improve transgene expression persistence and 28S rRNA gene-targeted insertion of lentiviral vectors. PLoS ONE. 2023;18(1):e0280894.
pubmed: 36662822
pmcid: 9858087
doi: 10.1371/journal.pone.0280894
Becirovic E. Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications. Cell Mol Life Sci. 2022;79(2).
Chen Y, Zhang W, Bai X, Liu Y. Targeting the transcriptional activity of STAT3 by a novel fusion protein. BMC Cancer. 2022;22(1):751.
pubmed: 35810312
pmcid: 9271252
doi: 10.1186/s12885-022-09837-1
Lessard E, Rennie K, Haqqani A, Ling B, Whitfield J, Paradis A, Araujo J, Yoganathan N, Gillard J, Stanimirovic D, Chakravarthy B. Pharmacokinetics and pharmacodynamic effect of a blood-brain barrier-crossing fusion protein therapeutic for Alzheimer’s disease in rat and dog. Pharm Res. 2022;39(7):1497–507.
pubmed: 35704250
pmcid: 9246806
doi: 10.1007/s11095-022-03285-z
Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M, Kim S, Lee Y, Han KH, Chung W-S, Kim CH. Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein. Nat Med. 2022;28(9):1802–12.
pubmed: 35927581
doi: 10.1038/s41591-022-01926-9
Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, Giese T, Assimon VA, Chen X, Zhang Y, Solanoy H, Jenkins K, Sanchez PE, Kane L, Miyamoto T, Chew KS, Pizzo ME, Liang N, Calvert MEK, DeVos SL, Baskaran S, Hall S, Sweeney ZK, Thorne RG, Watts RJ, Dennis MS, Silverman AP, Zuchero YJY. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359.
pubmed: 32461332
doi: 10.1126/scitranslmed.aay1359
Goretzki A, Lin YJ, Meier C, Dorn B, Wolfheimer S, Jamin A, Schott M, Wangorsch A, Vieths S, Jakob T, Scheurer S, Schülke S. Stimulation of naïve B cells with a fusion protein consisting of FlaA and Bet v 1 induces regulatory B cells ex vivo. Allergy. 2023;78(3):663–81.
pubmed: 36196479
doi: 10.1111/all.15542
Ye X, Chen Y, Qi J, Zhu S, Wu Y, Xiong J, Hu F, Guo Z, Liang X. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol. 2023;952:175811.
pubmed: 37245859
doi: 10.1016/j.ejphar.2023.175811
Jiang S, Jia Z, Zheng Y, Zhang J, Li Z, Yu X, Zhang K, Bai Y, Guo W, Kong Y, Li Q. Bifunctional fusion protein targeting both FXIIa and FXIa displays potent anticoagulation effects. Life Sci. 2022;309:121021.
pubmed: 36208658
doi: 10.1016/j.lfs.2022.121021
Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marté JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, Madan RA, Schlom J, Gulley JL. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J ImmunoTherapy Cancer. 2020;8(2):e001395.
doi: 10.1136/jitc-2020-001395
Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer. 2020;8(1):e000564.
pubmed: 32461347
pmcid: 7254161
doi: 10.1136/jitc-2020-000564
Cho BC, Daste A, Ravaud A, Salas S, Isambert N, McClay E, Awada A, Borel C, Ojalvo LS, Helwig C, Rolfe PA, Gulley JL, Penel N. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. Jr ImmunoTherapy Cancer. 2020;8(2):e000664.
doi: 10.1136/jitc-2020-000664
Peper-Gabriel JK, Pavlidou M, Pattarini L, Morales-Kastresana A, Jaquin TJ, Gallou C, Hansbauer E-M, Richter M, Lelievre H, Scholer-Dahirel A, Bossenmaier B, Sancerne C, Riviere M, Grandclaudon M, Zettl M, Bel Aiba RS, Rothe C, Blanc V, Olwill SA. The PD-L1/4-1BB bispecific antibody–Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner. Clin Cancer Res. 2022;28(15):3387–99.
pubmed: 35121624
pmcid: 9662934
doi: 10.1158/1078-0432.CCR-21-2762
De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482–90.
pubmed: 17964218
doi: 10.1016/j.it.2007.07.011
Sperinde G, Montgomery D, Mytych DT. Clinical immunogenicity risk assessment for a fusion protein. AAPS J. 2020;22(3):64.
pubmed: 32246297
doi: 10.1208/s12248-020-00447-y
Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself. 2010;1(4):314–22.
pubmed: 21487506
pmcid: 3062386
doi: 10.4161/self.1.4.13904
Carrascosa J-M, Jacobs I, Petersel D, Strohal R. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8(2):173–94.
doi: 10.1007/s13555-018-0230-9
Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–55.
pubmed: 32236956
pmcid: 7540323
doi: 10.1002/cpt.1836
Jenneck C, Novak N. The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. Ther Clin Risk Manag. 2007;3(3):411–20.
pubmed: 18488075
pmcid: 2386357
Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology. 2010;50(3):437–49.
pubmed: 20876701
pmcid: 3042254
doi: 10.1093/rheumatology/keq287
Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71(5):639–41.
pubmed: 21375570
pmcid: 3093069
doi: 10.1111/j.1365-2125.2011.03958.x
Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW. A review of romiplostim mechanism of action and clinical applicability. Drug Des Dev Ther. 2021;15:2243–68.
doi: 10.2147/DDDT.S299591
Lombardi Y, François H. Belatacept in kidney transplantation: what are the true benefits? A systematic review. Front Med (Lausanne). 2022;9:942665.
pubmed: 35911396
doi: 10.3389/fmed.2022.942665
Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23(16):9424.
pubmed: 36012690
pmcid: 9409486
doi: 10.3390/ijms23169424
Mansour AM, Stewart MW, Farah ME, Mansour HA, Chhablani J. Ziv-aflibercept: a cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor. Acta Ophthalmol. 2020;98(5):e540–8.
pubmed: 31863550
doi: 10.1111/aos.14328
Keam SJ. Efanesoctocog alfa: first approval. Drugs. 2023;83(7):633–8.
pubmed: 37022666
pmcid: 10238336
doi: 10.1007/s40265-023-01866-9
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WHH, Temelkova-Kurktschiev T. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20(1):42–9.
pubmed: 28573765
doi: 10.1111/dom.13028
Bowden SA, Foster BL. Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy. Drug Des Dev Ther. 2018;12:3147–61.
doi: 10.2147/DDDT.S154922
Lamb YN, Hoy SM. Eftrenonacog alfa: a review in haemophilia B. Drugs. 2023;83(9):807–18.
pubmed: 37081241
pmcid: 10247827
doi: 10.1007/s40265-023-01868-7
Kubasch AS, Fenaux P, Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv. 2021;5(5):1565–75.
pubmed: 33687432
pmcid: 7948289
doi: 10.1182/bloodadvances.2020002177
Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, Hlalah O, Mehmi I, Chawla S, Hasal SJ, Yang Z, Cobb PW. Eflapegrastim, a long-acting granulocyte-colony stimulating factor for the management of chemotherapy-induced neutropenia: results of a phase III trial. Oncologist. 2020;25(8):e1233–41.
pubmed: 32476162
pmcid: 7418343
doi: 10.1634/theoncologist.2020-0105
Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Bush MA. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–7.
pubmed: 18812476
doi: 10.1210/jc.2008-1518
Lyseng-Williamson KA. Coagulation factor IX (Recombinant), albumin fusion protein (Albutrepenonacog alfa; Idelvion(®)): a review of its use in haemophilia B. Drugs. 2017;77(1):97–106.
pubmed: 27988873
doi: 10.1007/s40265-016-0679-8
Helleberg H, Lindecrona RH, Thygesen P, Bjelke M. Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats. Eur J Pharm Sci. 2022;168:106032.
pubmed: 34610450
doi: 10.1016/j.ejps.2021.106032
Fares FA, Suganuma N, Nishimori K, Lapolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci. 1992;89(10):4304–8.
pubmed: 1374895
pmcid: 49070
doi: 10.1073/pnas.89.10.4304
Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717–28.
pubmed: 35405011
pmcid: 9202717
doi: 10.1210/clinem/dgac220
Figgitt DP, Lamb HM, Goa KL. Denileukin diftitox. Am J Clin Dermatol. 2000;1(1):67–72.
pubmed: 11702307
doi: 10.2165/00128071-200001010-00008
Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R. FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26(3):532–6.
pubmed: 31548341
doi: 10.1158/1078-0432.CCR-19-2329
Dhillon S. Avalglucosidase alfa: first approval. Drugs. 2021;81(15):1803–9.
pubmed: 34591286
doi: 10.1007/s40265-021-01600-3
Hua G, Carlson D, Starr JR. Tebentafusp-tebn: a novel bispecific T-cell engager for metastatic uveal melanoma. J Adv Pract Oncol. 2022;13(7):717–23.
pubmed: 36199496
pmcid: 9514125
doi: 10.6004/jadpro.2022.13.7.8